SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx is trending as Gilead Sciences announced its acquisition for $7.8 billion, with the community focusing on the substantial premium and the strategic value of Arcellx's promising CAR T-cell therapy, anito-cel, which has shown strong clinical data for multiple myeloma.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for AXS-05 in Alzheimer's disease agitation, setting an April PDUFA date, alongside robust Q4 earnings and strong commercial growth for its CNS therapies. The community is highly optimistic about AXS-05's market potential and the company's trajectory towards cash flow positivity, further supported by multiple analyst upgrades and pipeline advancements.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's is trending after reporting Q4 earnings with strong revenue and a dividend increase, though an EPS miss has fueled community debate over its "Hungry for MORE" strategy driving market share gains against competitive and macro pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Increases Holdings in Tandem Diabetes Care, Inc. $TNDM

Aberdeen Group plc increased its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 67.9% in the third quarter, according to its most recent disclosure with the Securities and...

Why Tandem Diabetes Care Stock Popped Today

Key PointsTandem saw robust demand for its insulin pumps in the fourth quarter...

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up on Strong Earnings

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up on Better-Than-Expected Earnings...

Stifel Nicolaus Issues Positive Forecast for Tandem Diabetes Care (NASDAQ:TNDM) Stock Price

Stifel Nicolaus increased their price objective on shares of Tandem Diabetes Care from $20.00 to $22.00 and gave the stock a "hold" rating in a research note on Friday...

TNDM Q4 Earnings & Revenues Beat Estimates, Gross Margin & Stock Up

Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.

SENS Eversense 365 Integrated With twiist Gains Full Availability

Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.

<ul class="summary-bullets"><li>The company's Q4 revenue of $290.4 million beat estimates, while U.S. revenue reached $210.5 million.</li><li>Tandem guided to $1.065 billion-$1.085 billion in revenue, incorporating $70 million-$80 million in pay-as-you-go headwinds in the U.S.</li><li>The insulin pumpmaker emphasized a shift toward a pharmacy-based, recurring revenue model.&nbsp;</li></ul>Shares of Tandem Diabetes Care, Inc. (TNDM) jumped about 5% after hours on Thursday as investors looked past a fourth-quarter (Q4) earnings miss and focused on record revenue, margins, and the insulin pumpmaker's shift toward a recurring, pharmacy-based revenue model.&nbsp;<a href="https://stocktwits.com/symbol/TNDM">TNDM stock</a> fell over 2% in Thursday’s regular session.<h2 class="st-heading-2">Strong US Demand Drives Growth</h2>Tandem reported Q4 revenue of $290.4 million, surpassing consensus estimates of $277.2 million and marking the strongest quarter in the company’s history. U.S. revenue reached $210.5 million, while worldwide pump shipments totaled 38,000, including 27,000 units in the U.S.The company reported a Q4 loss per share of $0.01, narrower than the $0.09 analysts had expected. However, it posted operating income of $8.3 million, or 3% of sales, alongside a record 58% gross margin.&nbsp;“Momentum built across the year and culminated in Q4 results where we set multiple records while delivering double-digit growth and improved profitability,” CEO John Sheridan said on the earnings call, adding that Tandem surpassed $1 billion in annual worldwide sales for the first time.<h2 class="st-heading-2">Tandem Full-Year Sales Top $1B</h2>For the full year, Tandem reported $1.015 billion in worldwide sales, more than 126,000 pump shipments, and gross margin expansion to 54%.&nbsp;During 2025, the company began the global commercial rollout of t:slim X2 integration with Abbott’s FreeStyle Libre 3 Plus sensor, launched Android mobile control for the Tandem Mobi system,&nbsp;and initiated direct commercial operations in select European countries. It also applied for FDA approval to expand Control-IQ+&nbsp;for use by women with diabetes during pregnancy.Tandem guided to 2026 revenue of $1.065 billion to $1.085 billion, below consensus of $1.10 billion. However, the company said that the outlook reflects intentional headwinds tied to its transition to a pay-as-you-go reimbursement model in the U.S. pharmacy channel.U.S. sales are projected at $730 million to $745 million, incorporating a $70 million to $80 million headwind from the pay-as-you-go shift, while international sales are expected to reach $335 million to $340 million.CFO Leigh Vosseller said on the call that the pay-as-you-go model removes upfront pump costs for patients and improves access, while gradually reshaping the business toward recurring, more predictable revenue. She added that this benefit may not be fully visible in 2026 sales figures.<h2 class="st-heading-2">Margins Set To Improve In 2026</h2>Tandem forecast gross margin of 56% to 57% and&nbsp;an adjusted EBITDA margin of 5% to 6% for 2026. The company said pump shipments, rather than revenue growth, will be the “clearest indicator” of progress in 2026, with U.S. shipments expected to rise 10% to 11%.On the call, Sheridan noted upcoming product and pipeline milestones, including broader sensor integrations, international scaling of the Mobi platform, and plans to launch a tubeless Mobi option later in 2026. He also reiterated the company’s plans to advance toward a fully closed-loop insulin delivery system.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TNDM was ‘extremely bullish’ amid a 1,050% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tndm_ss_png_c785cee119.webp" alt="tndm ss.png" width="972" height="142"><figcaption>TNDM sentiment and message volume as of February 20 | Source: Stocktwits</figcaption></figure>One&nbsp;<a href="https://stocktwits.com/labibaouf/message/645390457">user</a> expects the stock to cross the $30 level soon.<stembedurl>https://stocktwits.com/labibaouf/message/645390457</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Lambster2/message/645406116">said</a>, It's all about what's ahead. I think tomorrow it crosses $20.”<stembedurl>https://stocktwits.com/Lambster2/message/645406116</stembedurl>TNDM stock has declined 16% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Tandem Diabetes Care logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss?

For the full year, Tandem reported $1.015 billion in worldwide sales and over 126,000 pump shipments.

Equity

Tandem Diabetes Care Q4 Earnings Call Highlights

Tandem Diabetes Care (NASDAQ:TNDM) reported record fourth-quarter and full-year 2025 results while outlining a major shift in its U.S. reimbursement strategy that management said will reshape growth...

Tandem Diabetes Care (TNDM) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +80.51% and +5.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

TNDM
Tandem Diabetes Care Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNDM News

TNDMTandem Diabetes Care Inc